IperionX Limited (ASX:IPX) has remained one of the more closely followed names on the ASX in September 2026, as its push to build a domestic US titanium Supply chain gathers backing. The company produces titanium metal from scrap and mineral feedstocks using low-emission technology, targeting American defence and industrial markets. After a strong run tied to US government support and production milestones, IPX has continued to feature among actively traded ASX shares, with investors closely watching each step in its ambitious scale-up.

Latest Developments

IperionX operates across Virginia, Tennessee and Utah, and has aligned itself closely with US government priorities around domestic critical-minerals supply. In August 2026 the company announced it had secured a second US Army task order to accelerate industrial-scale American titanium production, reinforcing its defence-sector relationships.

Separately, in early August 2026 IperionX announced a proposal to redomicile its parent entity from Australia to the United States, a move that would shift its primary listing structure toward a direct Nasdaq common-stock listing. The company has stressed that the redomiciliation remains subject to shareholder, court, regulatory and exchange approvals and is not yet complete. IperionX has also been ramping production at its Virginia facility, with reporting through 2026 describing a move toward around-the-clock operations as Demand and government backing grew.

The redomiciliation reflects how central the US market has become to IperionX's identity, given that its Manufacturing base, key customers and government relationships are all located there.

What Could Come Next

Near-term catalysts include further production milestones at Virginia, progress on the second Army task order, additional customer or government agreements, and the outcome of the proposed US redomiciliation. Completion of the integrated project economic assessment, targeted around end-2026, would also be significant. Material developments would be disclosed through ASX and US regulatory filings.

Risks to Watch

IperionX faces execution risk as it scales a novel production process to industrial volumes, which can involve delays and cost overruns. It remains pre-profit and may require further capital. The proposed redomiciliation is subject to multiple approvals and is not guaranteed. Reliance on government programs introduces policy and contracting risk. As a high-expectation growth stock, the shares can be volatile and sensitive to any milestone slippage.

Conclusion

IperionX Limited (ASX:IPX) continues to advance an ambitious plan to establish low-emission American titanium production, supported by US Army task orders and a proposed shift toward a US listing. The stock's profile reflects both the strategic appeal and the execution demands of that vision. Investors will focus on production ramp, government engagement and the redomiciliation process as the key determinants of IPX's trajectory into 2027.